| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17425255.2011.545053 |
| P698 | PubMed publication ID | 21241198 |
| P2093 | author name string | Mario Pellegatti | |
| Sabrina Pagliarusco | |||
| P2860 | cites work | Gene expression in distinct regions of the heart | Q28142086 |
| Drug-induced phospholipidosis: issues and future directions | Q28246047 | ||
| Membrane transporters in drug development | Q29616802 | ||
| Autoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development | Q30890487 | ||
| Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. | Q33269196 | ||
| Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes | Q33465087 | ||
| Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. | Q50913576 | ||
| Kinetics of distribution and elimination of DDE in rats. | Q52448099 | ||
| Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. | Q53524045 | ||
| Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective | Q58215262 | ||
| Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy | Q33708056 | ||
| The significance of excursions above the ADI: duration in relation to pivotal studies | Q33794199 | ||
| Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs. | Q34125466 | ||
| Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT). | Q34446186 | ||
| Differential sensitivity of rat kidney and liver to fumonisin toxicity: organ-specific differences in toxin accumulation and sphingoid base metabolism | Q34513658 | ||
| Postmortem drug analysis: analytical and toxicological aspects. | Q34565977 | ||
| Comparative ototoxicity of ribostamycin, dactimicin, dibekacin, kanamycin, amikacin, tobramycin, gentamicin, sisomicin and netilmicin in the inner ear of guinea pigs | Q34644823 | ||
| Casopitant: a new warrior in the antiemetic crusade | Q34981239 | ||
| Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule | Q35574233 | ||
| Delivering antibacterials to the lungs: considerations for optimizing outcomes. | Q35627814 | ||
| Methods to assess tissue-specific distribution and metabolism of drugs. | Q35971915 | ||
| Drug localization and targeting with receptor microscopic autoradiography | Q35982251 | ||
| Drug tissue distribution: study methods and therapeutic implications | Q36321098 | ||
| Tissue distribution and pharmacodynamics: a complicated relationship | Q36384775 | ||
| Requirements for bioanalytical procedures in postmortem toxicology | Q36766468 | ||
| Post-mortem clinical pharmacology | Q36922235 | ||
| Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity | Q37201673 | ||
| Toxicity testing in the 21st century: bringing the vision to life | Q37346896 | ||
| Modelling and PBPK simulation in drug discovery | Q37413064 | ||
| Physiologically based pharmacokinetics (PBPK). | Q37550553 | ||
| Tachykinin receptor antagonists in clinical trials | Q37638682 | ||
| Role of reactive metabolites in drug-induced hepatotoxicity | Q37658448 | ||
| Approaches for minimizing metabolic activation of new drug candidates in drug discovery | Q37658491 | ||
| Rate and extent of drug accumulation after multiple dosing revisited. | Q37763073 | ||
| Human accumulation potential of xenobiotics: potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis | Q37831728 | ||
| Interspecies comparisons in toxicology: the utility and futility of plasma concentrations of the test substance | Q38011036 | ||
| Autoradiography: high-resolution molecular imaging in pharmaceutical discovery and development | Q38088766 | ||
| Imaging mass spectrometry: hype or hope? | Q38451237 | ||
| Binding of drugs to eye melanin is not predictive of ocular toxicity | Q40826253 | ||
| Progressive application of autoradiography in pharmacokinetic and metabolic studies for the development of new drugs | Q40955682 | ||
| Relations between toxicity and altered tissue distribution and urinary excretion of nicotine, cotinine, and hydroxycotinine after chronic oral administration of nicotine in rats. | Q43122195 | ||
| Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy | Q43266783 | ||
| Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1). | Q43832307 | ||
| Species specificity in the metabolism of nabilone. Relationship between toxicity and metabolic routes | Q44828810 | ||
| Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence | Q44942448 | ||
| Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon? | Q46240427 | ||
| Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing | Q46267572 | ||
| Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood. | Q50705385 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 137-146 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review | |
| P478 | volume | 7 |
| Q30828511 | 3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors |
| Q33553411 | A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging. |
| Q35825043 | An introduction to MS imaging in drug discovery and development |
| Q35704471 | Drug compound characterization by mass spectrometry imaging in cancer tissue |
| Q34646772 | Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. |
| Q38182903 | Foamy macrophage responses in the rat lung following exposure to inhaled pharmaceuticals: a simple, pragmatic approach for inhaled drug development |
| Q37522770 | Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging |
| Q39033781 | Imaging mass spectrometry in drug development and toxicology |
| Q27314740 | In situ mass spectrometry imaging and ex vivo characterization of renal crystalline deposits induced in multiple preclinical drug toxicology studies |
| Q39018486 | Mass spectrometry imaging: a novel technology in rheumatology |
| Q35936145 | Novel insights in drug metabolism by MS imaging |
| Q38123694 | Qualitative and quantitative mass spectrometry imaging of drugs and metabolites in tissue at therapeutic levels |
| Q35213962 | Spatial distribution of theobromine--a low MW drug--in tissues via matrix-free NALDI-MS imaging |
Search more.